Alaunos Therapeutics, Inc. - 8-K Filing

Alaunos Therapeutics regains Nasdaq compliance with $350 million financing following Velaris Therapeutics merger (Items: 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing)

SEC EDGAR ·

Tickers: $TCRT

Read the full article at SEC EDGAR

More Regulatory news